The hunter syndrome therapeutics market is anticipated to grow at a significant CAGR of 5.3% during the forecast period (2022-2028). Hunter syndrome, commonly known as mucopolysaccharidosis II or MPS II, is a rare condition caused by a lack of the lysosomal enzyme iduronate-2-sulfatase. The two primary methods for treatment of symptomatic relief and controlling problems […]
